Pliant Therapeutics (NASDAQ:PLRX) Reaches New 12-Month Low at $11.91

Pliant Therapeutics, Inc. (NASDAQ:PLRX)’s share price reached a new 52-week low on Wednesday . The company traded as low as $11.91 and last traded at $11.91, with a volume of 159953 shares. The stock had previously closed at $12.52.

Analysts Set New Price Targets

Several research firms recently commented on PLRX. Royal Bank of Canada boosted their price objective on shares of Pliant Therapeutics from $50.00 to $54.00 and gave the stock an “outperform” rating in a research note on Tuesday, March 5th. HC Wainwright reiterated a “buy” rating and issued a $48.00 price objective on shares of Pliant Therapeutics in a research note on Wednesday, February 28th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $38.00 price target on shares of Pliant Therapeutics in a report on Wednesday, April 10th. Nine investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Pliant Therapeutics has an average rating of “Buy” and a consensus target price of $49.00.

Pliant Therapeutics Trading Down 5.0 %

The business has a fifty day moving average price of $15.00 and a 200 day moving average price of $15.59. The company has a current ratio of 17.72, a quick ratio of 17.72 and a debt-to-equity ratio of 0.02. The firm has a market cap of $716.86 million, a PE ratio of -4.33 and a beta of 1.12.

Institutional Trading of Pliant Therapeutics

A number of large investors have recently bought and sold shares of the business. China Universal Asset Management Co. Ltd. lifted its position in Pliant Therapeutics by 97.3% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,529 shares of the company’s stock worth $27,000 after acquiring an additional 754 shares during the period. Quest Partners LLC acquired a new stake in shares of Pliant Therapeutics in the 4th quarter worth $37,000. Corton Capital Inc. acquired a new stake in Pliant Therapeutics in the third quarter valued at about $197,000. Rathbones Group PLC purchased a new position in shares of Pliant Therapeutics during the 3rd quarter worth approximately $203,000. Finally, Oppenheimer & Co. Inc. purchased a new stake in shares of Pliant Therapeutics in the third quarter valued at approximately $210,000. Institutional investors and hedge funds own 97.30% of the company’s stock.

Pliant Therapeutics Company Profile

Pliant Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis.